MarginsXMarginsX
Home › Markets › Health Care › INO

Inovio Pharmaceuticals Inc. (INO)

INO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.40
-2.10% on the day
Market cap
$262.2M
Micro cap
Revenue · 2025
$65K
-70.0% on 2024
Net income · 2025
-$84.9M
-130000.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/0001055726-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerINO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001055726
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$65K
Net income-$84.9M
Operating income-$86.8M
Net margin-130000.0%
Operating margin-132871.3%
Revenue growth-70.0%
Cash$44.3M
Total assets$74.3M
P/E (computed)Net income was not positive
P/S (computed)4013.1×

Warning signs

Cash runway
7.6 months
$47.0M cash at September 30, 2026
Share count, 1 year
+249.6%
2025-11-07 to 2026-11-10 · +723.4% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"In light of these factors, management believes that there is substantial doubt about the Company's ability to continue as a going concern beyond the fourth quarter of 2027."
10-Q 2026-11-10
Cash and burn$47.0M cash; operating cash flow -$18.6M a quarter.Report 2026-09-30
Shares outstanding187,306,884 (2026-11-10); 53,571,675 a year earlier; 272,986,424 three years earlier. 3y figure adjusted for splits (1-for-12 overall).Cover page 2026-11-10
Reverse splits, 3 years1; latest 1-for-12 on 2024-01-25Source 2024-01-25
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 7 424B5 takedowns, 6 at the marketLatest 2026-11-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$299K-$49.2M-$15.3M$47.0MNo debt tags$299K10-Q 2026-11-10
Q2 2026
2026-06-30
$0-$6.0M-$18.0M$31.5MNo debt tags$010-Q 2026-08-12
Q1 2026
2026-03-31
$0-$19.7M-$21.6M$26.3MNo debt tags$010-Q 2026-05-13
Q4 2025
2025-12-31
$0$3.8M-$19.4M$44.3MNo debt tags$65K10-K 2026-03-12
Q3 2025
2025-09-30
$0-$45.5M-$21.6M$36.6MNo debt tags$182K10-Q 2026-11-10
Q2 2025
2025-06-30
$0-$23.5M-$20.8M$24.4MNo debt tags$182K10-Q 2026-08-12
Q1 2025
2025-03-31
$65K-$19.7M-$26.9M$39.9MNo debt tags$283K10-Q 2026-05-13
Q4 2024
2024-12-31
$117K-$19.4M-$19.7M$65.8M$0$218K10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-06
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEF 14A2026-04-07

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+17.2%
1 month+43.0%
3 months+58.9%
Year to date-17.8%
1 year-26.7%
From 52-week high-45.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TTRXTurn Therapeutics Inc.$8.55-8.51%$261.4M
PRLDPrelude Therapeutics Incorporated$3.41-1.16%$272.1M
QTTBQ32 Bio Inc.$8.29-4.82%$248.1M
LFCRLifecore Biomedical Inc.$6.42-0.08%$243.2M
FULCFulcrum Therapeutics Inc.$3.71-1.59%$283.4M
CAMPCAMP4 Therapeutics Corporation$3.86+1.58%$242.2M
RCKTRocket Pharmaceuticals Inc.$2.16-6.09%$241.2M
BIOABioAge Labs Inc.$5.22-5.95%$239.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier